Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 167

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 167
---
 their
officers, directors, members, employees, and agents, successors and assigns, and each other person, if any, who controls such participating holder within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), under
the registration statement from certain losses, claims, damages, liabilities and expenses incident to Aadi’s obligations under the Registration Rights Agreement.

The foregoing summary of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the Registration
Rights Agreement, attached as to this proxy statement and incorporated herein by reference.

The License Agreement

Pursuant
to the License Agreement with WuXi Biologics, dated December 19, 2024, Aadi obtained an exclusive license to WuXi Biologics’ pre-clinical antibody drug conjugate programs targeting Mucin-16 (MUC16), Protein Tyrosine Kinase 7 (PTK7) and Seizure Related 6 Homolog (SEZ6), in each case, leveraging Hangzhou DAC’s linker-payload technology.

License

Under the License Agreement, WuXi
Biologics granted Aadi an exclusive (even as to WuXi Biologics and its affiliates), royalty-bearing, transferable and sublicensable license under certain patents, know-how and other intellectual property to
develop and commercialize certain antibody-drug conjugates targeting each of MUC16, PTK7, and SEZ6 and certain licensed products incorporating such antibody-drug conjugates for any and all indications worldwide. Aadi has agreed to use commercially
reasonable efforts to develop and commercialize licensed product(s) within each ADC Program within certain periods of time and within certain major markets. Aadi may obtain extensions to the certain periods of time in which it must achieve its
diligence obligations as specified in the License Agreement.

Economics

We were required to pay WuXi Biologics an initial upfront payment of $6 million in connection with the execution of the License Agreement. In addition, we
are required to pay WuXi Biologics an additional non-refundable, upfront payment of $38 million within ninety (90) days after execution of the License Agreement, which may be extended by either party
for an additional thirty (30) days.

Pursuant to the License Agreement, WuXi Biologics is eligible to receive from us (a) up to an aggregate of
$265 million upon the achievement of certain development milestones, and (